Breaking events

Pharma

NUCE International 2014

News-Image

Sep. 8 - 10, 2014 Bologna/Italy

Pharma

CESPT 2014

News-Image

Sep. 18 - 20, 2014 Portorož/Slovenia

Pharma

CPhI Worldwide 2014

News-Image

Oct. 7 - 9, 2014 Paris/France

Sustained Release



Matrix-Systems

 

Do you need to develop a matrix system for controlled release applications?
 
Our solution:  Metolose SR = (HPMC)

Metolose SR has more refined specifications in terms of degree of substitution and a finer particle size than regular Metolose. This makes it an ideal application for a hydrophilic matrix system, both in direct compression and in wet granulation.

 

 

High-Viscosity HPMC 

 

Are you looking for an excipient with hydrogel-forming properties?

 

Our solution: Metolose SM,  Metolose SH = (HPMC)

 

The highly viscous SH-types exhibit hydrogel-forming properties. In addition they have water-retention properties and feature reversible thermal gelation.

 

 

Polyethylenoxide

 

An alternative approach to diffusion-controlled release systems might be Polyethylenoxide (PEO). Please consult with us!

 

 

The easy way 

 

Adding Value - Cost and Time Saving 

 

EuRelease: Sustained Release "SR" formulations are widely used as they add value to pharmaceutical products. They benefit pharmaceutical companies, manufacturers and of course the patients. The R & D work to establish such products is tedious, time-consuming and expensive.

 

EuRelease from HARKE Pharma reduces these issues as the API release is dependent on only two variables: Quantity of EuRelease and tablet size.

 

EuRelease contains only high viscous hypromellose (E 464) and microcrystalline cellulose (E 460) in variable proportions. All materials fully comply to major pharmacopeias and have food status. The mixing process is aligned to HACCP - xGMP will be available upon request.

 

Contact us to find out how you can add value to your Nutraceutical, OTC or even Rx products with our vast experience in the field of SR and EuRelease!